NGLFINE vs SHILPAMED: Stock Comparison
SHILPA MEDICARE is the larger company by market capitalisation. NGL FINE CHEM shows a lower P/E, a higher ROE and faster revenue growth, while SHILPA MEDICARE shows a higher dividend yield, lower leverage and a higher net margin. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
NGLFINE leads 7; SHILPAMED leads 6 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | NGLFINE | SHILPAMED |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceuticals | Pharmaceuticals |
Price
| Metric | NGLFINE | SHILPAMED |
|---|---|---|
| Live Price | ₹2,907.5 | ₹964.15 |
| Day Change | -1.13% | 0.84% |
| Volume | 7,107 | 6.53 L |
| 52-Week High | ₹3,602 | ₹966.45 |
| 52-Week Low | ₹1,271 | ₹259.5 |
| Distance from 52W High | -19.28% | -0.24% |
Valuation
| Metric | NGLFINE | SHILPAMED |
|---|---|---|
| Market Cap | ₹1,804 Cr | ₹18,776 Cr |
| P/E Ratio | 30.41x | 61.25x |
| P/B Ratio | 5.28x | 7.03x |
| EPS | ₹29.78 | ₹5.16 |
| Book Value | ₹532.9 | ₹132.49 |
| Dividend Yield | 0.07% | 0.11% |
Growth
| Metric | NGLFINE | SHILPAMED |
|---|---|---|
| Revenue Growth (TTM YoY) | 57.2% | 31.5% |
| EPS Growth (TTM YoY) | 1,539.8% | 644.6% |
| Qtr Sales Growth | 1.79% | 146.39% |
| Qtr Profit Growth | 11.83% | 55.39% |
Profitability & Leverage
| Metric | NGLFINE | SHILPAMED |
|---|---|---|
| ROE | 13.01% | 5.1% |
| ROCE | 10.54% | 5.31% |
| Net Margin | 9.59% | 15.82% |
| Operating Margin | 12.08% | 27.86% |
| Debt to Equity | 0.34x | 0.05x |
Shareholding
As of Jun 2026 • change vs previous quarter| Metric | NGLFINE | SHILPAMED |
|---|---|---|
| Promoter Holding | 72.49%▼ 0.25 pp | 40.13% |
| FII Holding | 0.05%▲ 0.02 pp | 11.38%▲ 0.3 pp |
| DII Holding | 0.02%▲ 0.02 pp | 8.05%▼ 0.53 pp |
| Public Holding | 27.43%▲ 0.19 pp | 40.43%▲ 0.22 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: NGL FINE CHEM and SHILPA MEDICARE.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.